Clinical Trials
6 trialsNCT07194980 2026-06-05
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06136559 2026-05-28
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04728893 2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06863402 2026-05-20
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05947851 2026-05-18
BELLWAVE-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07583810 2026-05-15
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting